Disc Medicine, Inc. has recently filed a Form 144 with the SEC, detailing the sale of 6,965 shares of its common stock by Atlas Venture Fund X, L.P. This filing, dated October 20, 2026, is significant as it reflects the ongoing activities of major shareholders within the company.
The sale is valued at approximately $549,747.45, indicating substantial investor interest in the company. This move not only highlights the liquidity of Disc Medicine's shares but also underscores the dynamic nature of the pharmaceutical preparations industry, where strategic transactions can influence market perceptions and investor confidence.
Background
Disc Medicine, Inc. operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol IRON. It is categorized as a large accelerated filer and has been actively engaging with the SEC through various filings, including recent 8-K and 4 forms.
What the Filing Says
The Form 144 filing states, "The number of units sold is 6,965, with an aggregate market value of $549,747.45." This transaction is part of the ongoing activities of Atlas Venture Fund X, L.P., which has been a significant shareholder in Disc Medicine.
Impact
This sale may have implications for both the company and its investors. Shareholders may view this transaction as a sign of confidence or concern regarding the company's future performance. Additionally, the pharmaceutical preparations industry may observe this activity as indicative of broader trends in investment and shareholder engagement.
What's Next
The filing does not specify what happens next regarding this transaction or any future plans from Disc Medicine, Inc.
For more details, refer to the SEC filing with accession number 0001628280-26-066535.